D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 152 Citations 91,572 703 World Ranking 408 National Ranking 248

Research.com Recognitions

Awards & Achievements

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

Eric P. Winer mainly investigates Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. His Internal medicine research includes elements of Gynecology and Surgery. His research integrates issues of Chemotherapy regimen, Radiation therapy and Adjuvant therapy in his study of Breast cancer.

His Oncology research incorporates elements of Clinical trial, Trastuzumab, Randomized controlled trial, Paclitaxel and Mastectomy. His Cancer study combines topics from a wide range of disciplines, such as Germline mutation and Pathology. His study looks at the relationship between Chemotherapy and fields such as Anthracycline, as well as how they intersect with chemical problems.

His most cited work include:

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
  • American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer (1459 citations)
  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 (1248 citations)

What are the main themes of his work throughout his whole career to date?

Eric P. Winer mainly focuses on Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer. His studies examine the connections between Internal medicine and genetics, as well as such issues in Surgery, with regards to Cohort. His study in Breast cancer is interdisciplinary in nature, drawing from both Stage, Gynecology and Disease.

His Oncology research integrates issues from Adjuvant therapy, Regimen, Paclitaxel and Phases of clinical research. Eric P. Winer combines subjects such as Adverse effect, Family medicine and Pathology with his study of Cancer. His Metastatic breast cancer research is multidisciplinary, relying on both Cancer research, Tolerability, Letrozole, Clinical endpoint and Fulvestrant.

He most often published in these fields:

  • Internal medicine (70.91%)
  • Breast cancer (71.02%)
  • Oncology (61.70%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (70.91%)
  • Breast cancer (71.02%)
  • Oncology (61.70%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Breast cancer, Oncology, Metastatic breast cancer and Cancer. His work carried out in the field of Breast cancer brings together such families of science as Stage, Adverse effect, Cancer research and Clinical trial. The study incorporates disciplines such as Pembrolizumab, Hormone receptor, Trastuzumab and Chemotherapy in addition to Oncology.

His work deals with themes such as Regimen and Capecitabine, which intersect with Trastuzumab. His Metastatic breast cancer course of study focuses on PARP inhibitor and Reversion and Germline. His Cancer study incorporates themes from Bevacizumab, Epidemiology and Disease.

Between 2017 and 2021, his most popular works were:

  • Breast Cancer Treatment: A Review. (580 citations)
  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (494 citations)
  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (293 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Breast cancer

Breast cancer, Internal medicine, Oncology, Metastatic breast cancer and Cancer are his primary areas of study. The concepts of his Breast cancer study are interwoven with issues in Adverse effect, Capecitabine, Cohort and Immunotherapy. Eric P. Winer works mostly in the field of Cohort, limiting it down to concerns involving Disease and, occasionally, Radiation therapy.

Eric P. Winer interconnects Clinical trial, Pertuzumab, Trastuzumab, Chemotherapy and Randomized controlled trial in the investigation of issues within Oncology. The various areas that Eric P. Winer examines in his Metastatic breast cancer study include Exome sequencing, Cancer research, PARP inhibitor, Germline and Letrozole. His Cancer study combines topics in areas such as Drug, Drug resistance and PTEN.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)

2956 Citations

American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer

Gary H. Lyman;Armando E. Giuliano;Mark R. Somerfield;Al B. Benson.
Journal of Clinical Oncology (2005)

2079 Citations

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis.
Journal of Clinical Oncology (2003)

2000 Citations

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi.
Lancet Oncology (2010)

1610 Citations

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

A. S. Coates;E. P. Winer;A. Goldhirsch;R. D. Gelber.
Annals of Oncology (2015)

1586 Citations

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff.
Journal of Clinical Oncology (2002)

1501 Citations

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

Philip W. Kantoff;Susan Halabi;Mark Conaway;Joel Picus.
Journal of Clinical Oncology (1999)

1112 Citations

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

Daniel P. Silver;Andrea L. Richardson;Aron C. Eklund;Zhigang C. Wang.
Journal of Clinical Oncology (2010)

1075 Citations

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap.
The New England Journal of Medicine (2016)

1054 Citations

American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

Harold J. Burstein;Ann Alexis Prestrud;Jerome Seidenfeld;Holly Anderson.
Journal of Clinical Oncology (2010)

1036 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Eric P. Winer

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 192

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 174

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 167

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 160

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 153

Hope S. Rugo

Hope S. Rugo

University of California, San Francisco

Publications: 148

Ann H. Partridge

Ann H. Partridge

Harvard University

Publications: 144

Daniel F. Hayes

Daniel F. Hayes

University of Michigan–Ann Arbor

Publications: 132

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 127

Michael Untch

Michael Untch

University of Miami

Publications: 119

Javier Cortes

Javier Cortes

Vall d'Hebron Hospital Universitari

Publications: 117

Michael Gnant

Michael Gnant

Medical University of Vienna

Publications: 117

Marco Colleoni

Marco Colleoni

European Institute of Oncology

Publications: 116

Lajos Pusztai

Lajos Pusztai

Yale University

Publications: 112

Monica Morrow

Monica Morrow

Memorial Sloan Kettering Cancer Center

Publications: 111

Sibylle Loibl

Sibylle Loibl

Goethe University Frankfurt

Publications: 111

Trending Scientists

Szymon Rusinkiewicz

Szymon Rusinkiewicz

Princeton University

Oliver Lemon

Oliver Lemon

Heriot-Watt University

Jinyuan Zhou

Jinyuan Zhou

Lanzhou University

Peter D. Drummond

Peter D. Drummond

Swinburne University of Technology

Peng Jiang

Peng Jiang

Chinese Academy of Sciences

John Jaenike

John Jaenike

University of Rochester

Åke Hagström

Åke Hagström

Linnaeus University

Peter R. Robichaud

Peter R. Robichaud

United States Department of Agriculture

She-Jun Chen

She-Jun Chen

Chinese Academy of Sciences

Joel C. Bornstein

Joel C. Bornstein

University of Melbourne

Yuan Xiang Tao

Yuan Xiang Tao

Rutgers, The State University of New Jersey

Jeffrey S. Ashby

Jeffrey S. Ashby

Georgia State University

Alfred F. Michael

Alfred F. Michael

University of Minnesota

Ashish Khanna

Ashish Khanna

Maharaja Agrasen Institute of Technology (MAIT)

Scott B. MacKenzie

Scott B. MacKenzie

Indiana University

Allen Schick

Allen Schick

University of Maryland, College Park

Something went wrong. Please try again later.